Trends and risk factors of lung cancer in China

He, Siyi; Li, He; Cao, Maomao; Sun, Dianqin; Lei, Lin; Li, Ni; Peng, Ji; Chen, Wanqing

doi:10.21147/j.issn.1000-9604.2020.06.02

Cited by 30 publications

(27 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer and is one of the leading causes of cancer-related death ( 1 - 4 ). Chemotherapy has played a cornerstone role in the history of NSCLC therapy since the 20 th century ( 5 - 7 ).…”

Section: Introductionmentioning

confidence: 99%

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update

Lü¹,

Chu²,

Liu³

et al. 2022

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

Objective Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies are an effective means of treating non-small cell lung cancer (NSCLC). Here, we aim to update the equivalent efficacy assessment between QL1101 and bevacizumab based on two-year follow-up data. Methods In total, 535 eligible NSCLC patients were enrolled in this randomized controlled trial. Patients were randomly assigned 1:1 to the QL1101 group and the bevacizumab group. The full end time of this study was defined as 24 months after the last enrolled patient was randomized. The primary endpoint was the objective response rate (ORR); equivalence was confirmed if the two-sided 90% confidence interval (90% CI) of the relative risk was within the range of 0.75−1.33. The secondary endpoints were progression-free survival (PFS) and overall survival (OS). Results The two-year updated data showed similar ORR (QL1101 vs. bevacizumab: 53.1% vs. 54.3%; relative risk=0.977; 90% CI: 0.838−1.144), PFS (235 d vs. 254 d, log-rank P=0.311), and OS (577 d vs. 641 d, log-rank P=0.099) results between the QL1101 group and the bevacizumab group. The mean shrinkage ratio of targeted lesions was also similar between the QL1101 group and the bevacizumab group (22.5% vs. 23.5%). For patients who received QL1101 maintenance therapy, similar results were shown between the QL1101 group (n=157) and the bevacizumab group (n=148) (PFS: 253 d vs. 272 d, log-rank P=0.387; OS: 673 d vs . 790 d, log-rank P=0.101; mean tumor shrinkage rate: 26.6% vs. 27.5%). Conclusions This study reported that QL1101 had similar efficacy in treating nonsquamous NSCLC in terms of ORR, PFS and OS based on two-year updated data, providing a basis for the clinical application of QL1101.

show abstract

Section: Introductionmentioning

confidence: 99%

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update

Lü¹,

Chu²,

Liu³

et al. 2022

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

“…2 In 2015, 787,000 patients in China were newly diagnosed with lung cancer and 631,000 patients died of this disease, accounting for 20.03% of patients diagnosed with cancer and 26.99% who died of cancer during that year. 3 In addition, the burden of lung cancer has increased in the past three decades. Lung cancer is one of the most aggressive malignant tumors, with a 5-year overall survival (OS) rate of about 19.7%, 4 much lower than the 5-year OS rate of 40.5% among all cancer patients in China.…”

Section: Introductionmentioning

confidence: 99%

“…Lung cancer is one of the most aggressive malignant tumors, with a 5-year overall survival (OS) rate of about 19.7%, 4 much lower than the 5-year OS rate of 40.5% among all cancer patients in China. 3 In the treatment process, patients with lung cancers will suffer from the disease’s malignant degree and its therapy toxicity. 5 At present, the leading treatment methods for lung cancer patients include surgery, chemotherapy, radiotherapy, and targeted therapy.…”

Section: Introductionmentioning

confidence: 99%

Health-Related Quality of Life and Utility Scores of Lung Cancer Patients Treated with Traditional Chinese Medicine in China

Liu¹,

Wei²,

Teng³

et al. 2022

PPA

View full text Add to dashboard Cite

“…Lung cancer has the highest incidence and mortality rates worldwide among all cancers [1]. According to estimates, the incidence of lung cancer will linearly increase over the next 20 years [2,3]. Therefore, prevention and treatment of lung cancer is important.…”

Section: Introductionmentioning

confidence: 99%

TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment

Guo

Bai

Shi

et al. 2021

IJMS

View full text Add to dashboard Cite

Lung cancer has the highest rate of incidence and mortality among all cancers. Most chemotherapeutic drugs used to treat lung cancer cause serious side effects and are susceptible to drug resistance. Therefore, exploring novel therapeutic targets for lung cancer is important. In this study, we evaluated the potential of TMEM16A as a drug target for lung cancer. Homoharringtonine (HHT) was identified as a novel natural product inhibitor of TMEM16A. Patch-clamp experiments showed that HHT inhibited TMEM16A activity in a concentration-dependent manner. HHT significantly inhibited the proliferation and migration of lung cancer cells with high TMEM16A expression but did not affect the growth of normal lung cells in the absence of TMEM16A expression. In vivo experiments showed that HHT inhibited the growth of lung tumors in mice and did not reduce their body weight. Finally, the molecular mechanism through which HHT inhibits lung cancer was explored by western blotting. The findings showed that HHT has the potential to regulate TMEM16A activity both in vitro and in vivo and could be a new lead compound for the development of anti-lung-cancer drugs.

show abstract

Trends and risk factors of lung cancer in China

Cited by 30 publications

References 46 publications

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update

Health-Related Quality of Life and Utility Scores of Lung Cancer Patients Treated with Traditional Chinese Medicine in China

TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment

Contact Info

Product

Resources

About